Difference between revisions of "GATA3"

GATA3 (view source)

Revision as of 20:23, 2 August 2020

3,669 bytes added , 20:23, 2 August 2020

m

T-cell marker

Mark

109

edits

@@ Line 22: / Line 22: @@
 **[[Lobular breast carcinoma]].<ref name=pmid24061521>{{Cite journal  | last1 = Ellis | first1 = CL. | last2 = Chang | first2 = AG. | last3 = Cimino-Mathews | first3 = A. | last4 = Argani | first4 = P. | last5 = Youssef | first5 = RF. | last6 = Kapur | first6 = P. | last7 = Montgomery | first7 = EA. | last8 = Epstein | first8 = JI. | title = GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. | journal = Am J Surg Pathol | volume = 37 | issue = 11 | pages = 1756-60 | month = Nov | year = 2013 | doi = 10.1097/PAS.0b013e31829cdba7 | PMID = 24061521 }}</ref>
 *[[Chromophobe renal cell carcinoma]] ~50% of cases.<ref name=pmid24145643/>
-*[[Trophoblastic tumours]] +ve.<ref>{{Cite journal  | last1 = Mirkovic | first1 = J. | last2 = Elias | first2 = K. | last3 = Drapkin | first3 = R. | last4 = Barletta | first4 = JA. | last5 = Quade | first5 = B. | last6 = Hirsch | first6 = MS. | title = GATA3 expression in gestational trophoblastic tissues and tumours. | journal = Histopathology | volume = 67 | issue = 5 | pages = 636-44 | month = Nov | year = 2015 | doi = 10.1111/his.12681 | PMID = 25753145 }}</ref>
+*[[Trophoblastic tumours]] +ve.<ref>{{Cite journal  | last1 = Mirkovic | first1 = J. | last2 = Elias | first2 = K. | last3 = Drapkin | first3 = R. | last4 = Barletta | first4 = JA. | last5 = Quade | first5 = B. | last6 = Hirsch | first6 = MS. | title = GATA3 expression in gestational trophoblastic tissues and tumours. | journal = Histopathology | volume = 67 | issue = 5 | pages = 636-44 | month = Nov | year = 2015 | doi = 10.1111/his.12681 | PMID = 25753145 }}</ref> including [[choriocarcinoma]].<ref>{{Cite journal  | last1 = Osman | first1 = H. | last2 = Cheng | first2 = L. | last3 = Ulbright | first3 = TM. | last4 = Idrees | first4 = MT. | title = The utility of CDX2, GATA3, and DOG1 in the diagnosis of testicular neoplasms: an immunohistochemical study of 109 cases. | journal = Hum Pathol | volume = 48 | issue =  | pages = 18-24 | month = Feb | year = 2016 | doi = 10.1016/j.humpath.2015.09.028 | PMID = 26772394 }}</ref>
+*Parathyroid - [[parathyroid hyperplasia]], [[parathyroid adenoma]], [[parathyroid carcinoma]].<ref name=pmid25046229>{{Cite journal  | last1 = Ordóñez | first1 = NG. | title = Value of GATA3 immunostaining in the diagnosis of parathyroid tumors. | journal = Appl Immunohistochem Mol Morphol | volume = 22 | issue = 10 | pages = 756-61 | month =  | year =  | doi = 10.1097/PAI.0000000000000007 | PMID = 25046229 }}</ref>
+*Salivary gland tumours <ref name=pmid23604756>{{Cite journal  | last1 = Schwartz | first1 = LE. | last2 = Begum | first2 = S. | last3 = Westra | first3 = WH. | last4 = Bishop | first4 = JA. | title = GATA3 immunohistochemical expression in salivary gland neoplasms. | journal = Head Neck Pathol | volume = 7 | issue = 4 | pages = 311-5 | month = Dec | year = 2013 | doi = 10.1007/s12105-013-0442-3 | PMID = 23604756 }}</ref>
+*Pheochromocytoma (~70%) vs adrenocortical carcinoma (<10%<ref name=pmid2837449>{{Cite journal  | last1 = Perrino | first1 = CM. | last2 = Ho | first2 = A. | last3 = Dall | first3 = CP. | last4 = Zynger | first4 = DL. | title = Utility of GATA3 in the differential diagnosis of pheochromocytoma. | journal = Histopathology | volume = 71 | issue = 3 | pages = 475-479 | month = Sep | year = 2017 | doi = 10.1111/his.13229 | PMID = 28374498 }}</ref>).
+*[[Brenner tumour]]s and [[Walthard cell rest]]s.<ref name=pmid25281026>{{Cite journal  | last1 = Roma | first1 = AA. | last2 = Masand | first2 = RP. | title = Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. | journal = Hum Pathol | volume = 45 | issue = 12 | pages = 2417-22 | month = Dec | year = 2014 | doi = 10.1016/j.humpath.2014.08.003 | PMID = 25281026 }}</ref>
+*[[Malignant mesothelioma]]s (58%<ref name=pmid24145643/>).
+*Most [[T-lymphocytes]].<ref name=pmid19151747>{{cite journal |vauthors=Ho IC, Tai TS, Pai SY |title=GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation |journal=Nat. Rev. Immunol. |volume=9 |issue=2 |pages=125–35 |date=February 2009 |pmid=19151747 |pmc=2998182 |doi=10.1038/nri2476 |url=}}</ref> Used as part of a wider panel of IHC to sub-type peripheral T-cell lymphoma, NOS.<ref name=pmid31562134>{{cite journal |vauthors=Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J |title=Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry |journal=Blood |volume=134 |issue=24 |pages=2159–2170 |date=December 2019 |pmid=31562134 |doi=10.1182/blood.2019000779 |url=}}</ref>
 ===Images===
 *[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444740/figure/F1/ GATA3 nuclear staining - urothelial carcinoma (nih.gov)].<ref name=pmid22982890/>
@@ Line 28: / Line 35: @@
 ==Negative==
 *[[Prostate carcinoma]].
+**Positive in benign prostate glands with radiation atypia.<ref name=pmid28316088>{{cite journal |vauthors=Tian W, Dorn D, Wei S, Sanders RD, Matoso A, Shah RB, Gordetsky J |title=GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall |journal=Histopathology |volume=71 |issue=1 |pages=150–155 |date=July 2017 |pmid=28316088 |doi=10.1111/his.13214 |url=}}</ref>
 *[[Squamous cell carcinoma of the lung]].<ref name=pmid22982890/>

Difference between revisions of "GATA3"

GATA3 (view source)

Revision as of 20:23, 2 August 2020

Navigation menu

Search